Total Payments
$7,664
2024 Payments
$1,222
Companies
12
Transactions
21
Medicare Patients
2,298
Medicare Billing
$265,511
Payment Breakdown by Category
Consulting$5,144 (67.1%)
Other$1,200 (15.7%)
Travel$952.25 (12.4%)
Food & Beverage$321.14 (4.2%)
Education$46.13 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,144 | 5 | 67.1% |
| Honoraria | $1,200 | 1 | 15.7% |
| Travel and Lodging | $952.25 | 5 | 12.4% |
| Food and Beverage | $321.14 | 6 | 4.2% |
| Education | $46.13 | 4 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $2,199 | 4 | $0 (2019) |
| Incyte Corporation | $1,775 | 2 | $0 (2021) |
| PFIZER INC. | $1,200 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $993.34 | 6 | $0 (2017) |
| GlaxoSmithKline, LLC. | $825.00 | 1 | $0 (2021) |
| BeiGene USA, Inc. | $525.00 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $87.50 | 1 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $16.06 | 1 | $0 (2024) |
| Nabriva Therapeutics, plc | $12.91 | 1 | $0 (2021) |
| Millennium Pharmaceuticals, Inc. | $12.04 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,222 | 3 | PFIZER INC. ($1,200) |
| 2022 | $612.50 | 2 | BeiGene USA, Inc. ($525.00) |
| 2021 | $2,290 | 4 | Incyte Corporation ($1,440) |
| 2019 | $2,199 | 4 | GENZYME CORPORATION ($2,199) |
| 2018 | $335.00 | 1 | Incyte Corporation ($335.00) |
| 2017 | $1,005 | 7 | Merck Sharp & Dohme Corporation ($993.34) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/04/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Education | Cash or cash equivalent | $6.11 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 05/06/2024 | PFIZER INC. | PADCEV (Biological) | Honoraria | Cash or cash equivalent | $1,200.00 | General |
| Category: Oncology | ||||||
| 01/29/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Education | In-kind items and services | $16.06 | General |
| Category: Hematology | ||||||
| 11/23/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 08/13/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $87.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/19/2021 | Nabriva Therapeutics, plc | Sivextro (Drug) | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: Oxazolidinone antibiotics | ||||||
| 08/17/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| 06/14/2021 | Incyte Corporation | MONJUVI (Drug) | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 06/19/2019 | GENZYME CORPORATION | JEVTANA (Drug) | Consulting Fee | Cash or cash equivalent | $2,019.00 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2019 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $136.00 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2019 | GENZYME CORPORATION | JEVTANA (Drug) | Travel and Lodging | Cash or cash equivalent | $33.64 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2019 | GENZYME CORPORATION | JEVTANA (Drug) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: ONCOLOGY | ||||||
| 04/17/2018 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $335.00 | General |
| 11/17/2017 | Millennium Pharmaceuticals, Inc. | ALUNBRIG (Drug) | Education | In-kind items and services | $12.04 | General |
| Category: Oncology | ||||||
| 07/11/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $90.60 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $32.14 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $618.86 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $199.15 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 467 | 732 | $359,757 | $60,439 |
| 2022 | 12 | 526 | 869 | $356,617 | $65,216 |
| 2021 | 13 | 671 | 1,120 | $359,668 | $82,692 |
| 2020 | 14 | 634 | 950 | $266,973 | $57,165 |
Total Patients
2,298
Total Services
3,671
Medicare Billing
$265,511
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 100 | 206 | $133,774 | $21,896 | 16.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 138 | 251 | $115,581 | $17,278 | 14.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 31 | $21,580 | $4,113 | 19.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 37 | 37 | $17,519 | $3,698 | 21.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 33 | 50 | $12,578 | $3,049 | 24.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $15,805 | $2,689 | 17.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 41 | 54 | $17,607 | $2,470 | 14.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 19 | $6,877 | $1,744 | 25.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $7,876 | $1,328 | 16.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 25 | 32 | $4,258 | $1,205 | 28.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 14 | 19 | $6,302 | $968.81 | 15.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 98 | 204 | $119,428 | $21,955 | 18.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 154 | 283 | $119,635 | $19,563 | 16.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 55 | 93 | $22,623 | $5,098 | 22.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 34 | 36 | $16,432 | $3,723 | 22.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $13,440 | $3,023 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 46 | 61 | $17,856 | $2,600 | 14.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 42 | 82 | $10,726 | $2,439 | 22.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $11,059 | $2,053 | 18.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 17 | 17 | $9,566 | $1,715 | 17.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 20 | $6,980 | $1,570 | 22.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 16 | 24 | $6,840 | $1,119 | 16.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 13 | 14 | $2,032 | $355.95 | 17.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 141 | 328 | $120,652 | $25,387 | 21.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 77 | 150 | $73,581 | $17,076 | 23.2% |
About Dr. Birendra Kumar, MD
Dr. Birendra Kumar, MD is a Internal Medicine healthcare provider based in Mankato, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063491066.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Birendra Kumar, MD has received a total of $7,664 in payments from pharmaceutical and medical device companies, with $1,222 received in 2024. These payments were reported across 21 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($5,144).
As a Medicare-enrolled provider, Kumar has provided services to 2,298 Medicare beneficiaries, totaling 3,671 services with total Medicare billing of $265,511. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Mankato, MN
- Active Since 01/10/2006
- Last Updated 09/09/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1063491066
Products in Payments
- JEVTANA (Drug) $2,199
- MONJUVI (Drug) $1,440
- PADCEV (Biological) $1,200
- KEYTRUDA (Biological) $993.34
- BRUKINSA (Drug) $525.00
- FARXIGA (Drug) $87.50
- REBLOZYL (Biological) $16.06
- Sivextro (Drug) $12.91
- ALUNBRIG (Drug) $12.04
- Rezlidhia (Drug) $6.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Mankato
Sandeep Khosa, Md, MD
Internal Medicine — Payments: $6,125
Internal Medicine $6,125
Dr. Bithika Ray, M.d, M.D
Internal Medicine — Payments: $1,175
Internal Medicine $1,175
Eric Storvick, Md, MD
Internal Medicine — Payments: $1,144
Internal Medicine $1,144
Manpreet Kanwar, Md, MD
Internal Medicine — Payments: $778.13
Internal Medicine $778.13
Gregory Byrd, Do, DO
Internal Medicine — Payments: $521.11
Internal Medicine $521.11
Dr. David Byrd, Md, MD
Internal Medicine — Payments: $483.28
Internal Medicine $483.28